

COMMUNICATION



Cite this: *Chem. Commun.*, 2020, 56, 7519

Received 5th February 2020,
Accepted 1st June 2020

DOI: 10.1039/d0cc00919a

rsc.li/chemcomm

An ethylene cross-bridged pentaazamacrocyclic and its Cu²⁺ complex: constrained ligand topology and excellent kinetic stability†

Anthony D. Shircliff,^a Benjamin P. Burke,^b Dustin J. Davilla,^a Gwendolyn E. Burgess,^a Faith A. Okorochoa,^a Alina Shrestha,^a Elisabeth M. A. Allbritton,^a Phillip T. Nguyen,^a Rachael L. Lamar,^a Donald G. Jones,^a Michael-Joseph Gorbet,^a Michael B. Allen,^a John I. Eze,^a Andrea T. Fernandez,^a Daniel Ramirez,^a Stephen J. Archibald,^b Timothy J. Prior,^c Jeanette A. Krause,^d Allen G. Oliver^e and Timothy J. Hubin^a*

Rigid and topologically constrained ethylene cross-bridged tetraazamacrocyclics have been increasingly utilised for thirty years as they form remarkably stable transition metal complexes for catalysis, biomedical imaging, and inorganic drug molecule applications. Extending these benefits to pentaazamacrocyclics has been achieved and a first transition metal complex prepared and structurally characterized.

Coordination chemists can maximise binding affinity in their metal–ligand complexes by first optimising the first-order complementarity factors (Fig. 1) that match ligand and metal ion properties: size, geometric preference, and electronic properties.¹ Ni(cyclam)²⁺ exemplifies these factors² as the ionic radius of Ni²⁺ fits nearly perfectly into the cyclam cavity; the square planar preference of d⁸ Ni²⁺ coincides with the arrangement of the cyclam's nitrogen donors; and the borderline hard/soft characteristics of the metal and ligand lead to favourable bonding. Yet the stability of this complex can be overcome to release the metal ion, as exemplified by the cyanide removal of Ni²⁺ in the classical synthesis of the free cyclam.²

Additional complex stability must utilise factors beyond complementarity, such as ligand/complex rigidity and increasing ligand topological complexity. These factors can be grouped into a constraint category¹ that unlike complementarity factors do not, or at least as of yet have not, been ultimately exploited. Ethylene cross-bridged tetraazamacrocyclics^{3,4} represent a successful effort

at pushing those boundaries forward, as the short ethylene cross-bridge rigidifies the macrocycle, particularly upon metal ion binding, as well as giving the ligand the topological properties of the classical cryptands (Fig. 2). Numerous studies^{5,6} have demonstrated that the first-row transition metal complexes of these ethylene cross-bridged tetraazamacrocyclics are among the most kinetically stable towards harsh acidic/basic conditions of known synthetic transition metal complexes. Yet, their tetradentate nature ensures labile coordination sites that allow reactivity and/or binding ability that has made these complexes favoured for catalytic,^{7–21} biomedical imaging,^{22–30} and inorganic drug compound^{31–35} applications.

The ethylene cross-bridged tetraazamacrocyclics introduced in the 1990's have become increasingly popular choices for applications requiring harsh aqueous conditions (365 references identified by SciFinder for an ethylene cross-bridged cyclam substructure (1); 684 references identified by SciFinder for an ethylene cross-bridged cyclen substructure (2)). We have added a new class of similarly topologically constrained azamacrocyclic, the ethylene cross-bridged pentaazamacrocyclic, to the toolbox for chemists in need of constructing stable transition metal complexes to survive under harsh conditions. It is our belief that the ethylene cross-bridged pentaazamacrocyclics, as exemplified by the novel synthesis and initial structural characterization of (3), as well as structural and stability characterization of a first transition metal complex presented here (Cu(3)²⁺), will have a similarly impactful future.

^a Department of Chemistry and Physics, Southwestern Oklahoma State University, 100 Campus Drive, Weatherford, OK, 73096, USA. E-mail: tim.hubin@swosu.edu

^b Positron Emission Tomography Research Centre, Department of Biomedical Sciences University of Hull Cottingham Road Hull, HU6 7RX, UK

^c Department of Chemistry, University of Hull, Cottingham Road, Hull, HU6 7RX, UK

^d Department of Chemistry, University of Cincinnati, 301 Clifton Ct., Cincinnati, OH 45221-0172, USA

^e Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA

† Electronic supplementary information (ESI) available. CCDC 1981500, 1917395 and 1917396. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/d0cc00919a




Fig. 1 Graphical representation of the factors that can be optimized to produce increasing metal–ligand kinetic stability.




Fig. 2 Ethylene cross-bridged cyclam (**1**) and cyclen (**2**).

As pioneering practitioners of cross-bridged tetraazamacrocyclic chemistry, we have seen their increased use and sophistication, which has led us to consider additional opportunities to influence the field. It occurred to us that analogous ethylene cross-bridged pentaazamacrocycles – with an additional nitrogen donor, one open coordination site, and potentially similar stability properties – may provide a foundation for the development of a new generation of cross-bridged azamacrocyclic coordination chemistry (Fig. 3). Whereas cross-bridged cyclen (**2**) may be thought of as two fused TACN's, Me₃-CB-**15aneN5** (**3**) is a TACN fused with a cyclen. Simple methylation of the unbridged nitrogen atoms was our target, as the all-tertiary nitrogen ligands **1** and **2** are more stable than cross-bridged tetraazamacrocycles with secondary amines^{18,21} that are vulnerable to oxidation which provides a pathway for complex decomposition.³⁶ We also did not want additional donor-containing pendant arms as we targeted an open coordination site for potential binding of substrate or oxidants for catalysis.

Initial literature searching found no match for target **3**. However, the tris secondary amine analogue, H₃-CB-**15aneN5** (**4**) and various tris oxygen-donor pendant armed derivatives designed for biological imaging, have appeared in the patent literature.^{37–42} Due to the complexity and lack of details in the patent multistep synthetic routes and familiarity with the short and efficient glyoxal condensation route to ethylene cross-bridged tetraazamacrocycles,^{3,21,43} we hypothesized that a similar glyoxal condensation route to ethylene cross-bridged pentaazamacrocycles, similar to **1** and **2**, might be possible. Although less efficient than for tetraazamacrocycles due to complications from the fifth amine, this route was indeed successful (Fig. 4). Further, benzylation of **5** has allowed the independent synthesis, upon debenylation of the benzylation analogue of **3**, to yield **4** by our new glyoxal route. Production of this tris secondary amine will allow the addition of a variety of pendant arms to allow the same kind of spread of this ligand into other areas of chemistry. This work will be published later.

The synthesis of **3** may be best thought of as a “one-pot” approach. Multiple isomers of **5**, **6**, and **3** are likely present after each step. Yet, it appears either the multiple isomers converge to **3**, or those that don't can be removed upon extraction of **3** into a nonpolar organic solvent, while any quaternized amine products




Fig. 3 Me₃-CB-**15aneN5** (**3**) and H₃-CB-**15aneN5** (**4**).




Fig. 4 Synthetic route to Me₃-CB-**15aneN5** (**3**): (a) 1 eq. 40% aq. glyoxal, MeOH, 16 h, RT, 85% yield; (b) (i) 10 eq. MeI, MeCN, 5 d, RT; (ii) evaporate to solid, wash with DCM, not isolated—contains isomers; (c) (i) 20 eq. NaBH₄, 95% EtOH, 5 d, RT, N₂; (ii) 6 M HCl, evaporate, 30% aq. KOH, CHCl₃ extraction, 32% yield. Full experimental details and characterization data in ESI.†

remain in the aqueous layer. Although the full set of isomers at each step have not been fully characterized, the un-optimized “one-pot” approach yields **3** in high purity.

15aneN5 was synthesized by a modified literature method.⁴⁴ Two potential structural isomers were envisioned for the initial condensation of glyoxal with **15aneN5** (Fig. 5). Based on the analogous tetraazamacrocyclic chemistry where 6-membered rings are favoured, it was hypothesised that **5** (internal rings: 6,5,6,8), would be thermodynamically favoured over **5'** (internal rings: 5,6,5,9). Although only one major MS⁺ peak at *m/z* = 238 (LH⁺) was observed, the ¹H and ¹³C NMR spectra (see ESI†) gave evidence of more than a single isomer being present. For example, sixteen ¹³C signals were reproducibly observed even though the compound has only twelve carbon atoms. It is hypothesised that both **5** and **5'** are present (this would help explain four different ¹³C resonances between 78–86 ppm) and that additional *cis/trans* isomers (with respect to the two methyne protons of the two-carbon bridge) may also exist in the mixture. However, the synthetic route in Fig. 4 might reasonably be expected to succeed even with such a mixture of isomers, so no purification was attempted prior to continued reaction.

Many attempts were made to structurally characterize **5** without success. However, a byproduct of the methylation step (discussed below) to prepare **6** fortuitously crystallized and demonstrated the predicted glyoxal condensate connectivity (Fig. 6). This structure has two quaternary nitrogens: **N4** is dimethylated and **N1** is monomethylated. Fig. 6 also shows **H11** and **H12** in a *cis* relationship, a key to the cross-bridging synthesis of **1** and **2** (Fig. 1).^{3,21,43}

As expected if a mixture of isomers of **5** is used as the starting material, and as demonstrated in Fig. 6, the methylation of **5** shown in Fig. 4 does not proceed to only one product. Again based on experience with tetraazamacrocyclic systems, methylation was expected to proceed first with the secondary amine of **5** or **5'**, then




Fig. 5 Structural isomers possible for glyoxal condensation with **15aneN5**.




Fig. 6 X-ray crystal structure of a byproduct **6'**, a methylation isomer of **6** demonstrating the connectivity of glyoxal condensate **5**. Selected protons **H11** and **H12** shown.

at two non-adjacent tertiary nitrogens. The mixture of solid quaternary nitrogen salts (at least **6** and **6'**) was not purified as it was deemed simpler to purify the reduced neutral compound **3**. The crystallized byproduct **6'** notwithstanding, it appears that the predicted methylation product **6** is the major product, as **3** is realized as the major product of the reductive ring cleavage final step. Separation of the neutral **3** from the reduced product of **6'**, which would maintain at least one quaternary nitrogen (**N5**) and a positive charge, occurred during the extraction into chloroform from a highly basic aqueous phase.

An X-ray crystal structure of **3** was obtained and is shown in Fig. 7. In this figure, the fused nature of the TACN moiety on the left with the cyclen moiety on the right is evident. This structure contains a triprotonated trication of **3**, $\text{H}_3\text{3}^{3+}$, with one bridgehead nitrogen, **N5**, and two methylated nitrogens, **N2** and **N4** protonated. The protons all lie within the 3-dimensional cavity of the ligand, which is a familiar arrangement for protonated cross-bridged tetraazamacrocycles as well. This cavity is thus primed for transition metal complexation.

Complexation of **3** with Cu^{2+} utilized rigorously dry MeOH, under an inert atmosphere to prevent ligand protonation. To demonstrate the coordination properties of the ligand, the synthetic details of the Cu^{2+} complex are included in the ESI,[†] and an X-ray crystal structure of this complex, $\text{Cu}(\text{3})^{2+}$ is pictured in Fig. 8. The Cu^{2+} ion is engulfed in the cavity that was occupied by three protons in $\text{H}_3\text{3}^{3+}$. It is bound to all five nitrogens of **3** in a distorted square pyramidal structure with the four nitrogens of the cyclen moiety serving as the base of the pyramid and the remaining non-bridgehead nitrogen belonging to the TACN moiety serving as the apex of the pyramid. The τ_5 parameter quantifying the geometry of 5-coordinate transition metal complexes⁴⁵ is $\tau_5 = 0.03$, in agreement with the assignment of a square pyramidal coordination geometry. Typical Jahn–Teller distortion for d^9 Cu^{2+} is observed with the square base Cu1–N bond distances averaging 2.031 Å and the Cu1–N5 apical bond length of 2.168(6) Å.

Finally, a key property of ethylene cross-bridged tetraazamacrocycles resulting from their rigidity and topological constraint (*vide supra*) is the kinetic stability of their transition metal complexes under harsh conditions that would normally destroy complexes




Fig. 7 X-ray crystal structure of a $\text{H}_3\text{3}^{3+}$.




Fig. 8 Complexation scheme (TACN atoms are red, cyclen atoms are blue and atoms belonging to both rings are purple) and X-ray crystal structure of $\text{Cu}(\text{3})^{2+}$ illustrating the fused TACN (N1–N4–N5) and cyclen (N1–N2–N3–N4) moieties.[‡]

very quickly. This property has lately been systematically quantified using the half-life of the complex in 5 M HCl at various temperatures.^{18,21,27} For example, $\text{Cu}(\text{1})^{2+}$ in 5 M HCl at 50 °C has a half-life of 7.3 d, while the unbridged $\text{Cu}(\text{tmc})^{2+}$ (tmc = tetramethylcyclam) in 1 M HNO_3 at 25 °C has a half-life of only 2.0 s (see Table 1). We have determined the half-life of $\text{Cu}(\text{15aneN5})^{2+}$ in 5 M HCl at 50 °C as less than 2 minutes. Adding the ethylene cross-bridge dramatically increases the half-life of $\text{Cu}(\text{3})^{2+}$ under the same conditions to 5.3 d, a value very similar to that of $\text{Cu}(\text{1})^{2+}$. These results indicate that complexes of **3** should survive harsh conditions present in many catalytic and biomedical applications.

Preliminary complexation studies of **3** with a range of other transition metal ions (Cr^{2+} , Mn^{2+} , Fe^{2+} , Co^{2+} , Ni^{2+} , Zn^{2+}) has been successful, utilizing dry aprotic solvents, such as MeCN and DMF, under inert atmosphere to prevent ligand protonation. Understanding the syntheses and properties of these complexes is ongoing.

Acknowledgment is made to the Donors of the American Chemical Society Petroleum Research Fund for support of this research. TJH thanks the Henry Dreyfus Teacher-Scholar Awards Program for support of this work. BPB acknowledges the Royal Society of Chemistry JWT Jones Travelling Fellowship for support of this work. Crystallographic data were collected through the SCrALS (Service Crystallography at Advanced Light Source) program at the Small-Crystal Crystallography Beamline 11.3.1 at the Advanced Light Source (ALS), Lawrence Berkeley National Laboratory. The ALS is supported by the U.S. Department of Energy, Office of Energy Sciences Materials Sciences Division, under contract DE-AC02-05CH11231.

Table 1 Half-lives of selected copper(II) complexes in HCl

Ligand	25 °C 1 M HNO_3	50 °C 5 M HCl	Ref.
	2.0 seconds	—	46
	—	7.3 days	18
	—	< 2 minutes	This work
	—	5.3 days	This work

Conflicts of interest

There are no conflicts to declare.

Notes and references

‡ Selected bond lengths (Å) and angles (°): Cu(1)–N(1) 2.013(6); Cu(1)–N(2) 2.035(6); Cu(1)–N(3) 2.034(6); Cu(1)–N(4) 2.042(6); Cu(1)–N(5) 2.162(6); N(1)–Cu(1)–N(3) 152.3(2); N(1)–Cu(1)–N(2) 86.3(2); N(2)–Cu(1)–N(4) 154.1(2); N(2)–Cu(1)–N(5) 119.2(2); N(3)–Cu(1)–N(2) 87.9(2); N(1)–Cu(1)–N(4) 86.2(3); N(3)–Cu(1)–N(4) 87.3(3); N(1)–Cu(1)–N(5) 84.7(2); N(3)–Cu(1)–N(5) 121.5(2); N(4)–Cu(1)–N(5) 84.7(2).

- D. H. Busch, *Chem. Rev.*, 1993, **93**, 847–860.
- E. K. Barefield, F. Wagner, A. W. Herlinger and A. R. Dahl, *Inorg. Synth.*, 1976, **XVI**, 220–225.
- G. R. Weisman, M. E. Rogers, E. H. Wong, J. P. Jasinski and E. S. Paight, *J. Am. Chem. Soc.*, 1990, **112**(23), 8604–8605.
- A. Bencini, A. Bianchi, C. Bazzicalupi, M. Ciampolini, V. Fusi, M. Micheloni, N. Nardi, P. Paoli and B. Valtancoli, *Supramol. Chem.*, 1994, **3**.
- T. J. Hubin, *Coord. Chem. Rev.*, 2003, **241**, 27–46.
- J. Springborg, *Dalton Trans.*, 2003, 1653–1665.
- T. J. Hubin, J. M. McCormick, S. R. Collinson, M. Buchalova, C. M. Perkins, N. W. Alcock, P. K. Kahol, A. Raghunathan and D. H. Busch, *J. Am. Chem. Soc.*, 2000, **122**(11), 2512–2522.
- Y. Feng, J. England and L. Que, *ACS Catal.*, 2011, **1**(9), 1035.
- T. J. Hubin, J. M. McCormick, N. W. Alcock and D. H. Busch, *Inorg. Chem.*, 2001, **40**(3), 435–444.
- T. J. Hubin, J. M. McCormick, S. R. Collinson, N. W. Alcock, H. J. Clase and D. H. Busch, *Inorg. Chim. Acta*, 2003, **346**, 76–86.
- G. Yin, A. M. Danby, D. Kitko, J. D. Carter, W. M. Scheper and D. H. Busch, *Inorg. Chem.*, 2007, **46**, 2173–2180.
- G. C. Yin, A. M. Danby, D. Kitko, J. D. Carter, W. M. Scheper and D. H. Busch, *J. Am. Chem. Soc.*, 2008, **130**(48), 16245–16253.
- S. Chattopadhyay, R. A. Geiger, G. Yin, D. H. Busch and T. A. Jackson, *Inorg. Chem.*, 2010, **49**, 7530–7535.
- S. Shi, Y. J. Wang, A. H. Xu, H. J. Wang, D. J. Zhu, S. B. Roy, T. A. Jackson, D. H. Busch and G. C. Yin, *Angew. Chem., Int. Ed.*, 2011, **50**(32), 7321–7324.
- L. Dong, Y. Wang, Y. Lu, Z. Chen, F. Mei, H. Xiong and G. Yin, *Inorg. Chem.*, 2013, **52**, 5418–5427.
- G. Yin, *Acc. Chem. Res.*, 2013, **46**, 483–492.
- D. H. Busch, S. R. Collinson and T. Hubin, *US Pat.*, 6906189, 2005.
- D. G. Jones, K. R. Wilson, D. J. Cannon-Smith, A. D. Shircliff, Z. Zhang, Z. Q. Chen, T. J. Prior, G. C. Yin and T. J. Hubin, *Synth. Inorg. Chem.*, 2015, **54**(5), 2221–2234.
- Z. Zhang, K. L. Coats, Z. Q. Chen, T. J. Hubin and G. C. Yin, *Inorg. Chem.*, 2014, **53**(22), 11937–11947.
- S. M. Brewer, K. R. Wilson, D. G. Jones, E. W. Reinheimer, S. J. Archibald, T. J. Prior, M. A. Ayala, A. L. Foster, T. J. Hubin and K. N. Green, *Inorg. Chem.*, 2018, **57**, 8890–8902.
- D. L. Matz, D. G. Jones, K. D. Roewe, M. J. Gorbet, Z. Zhang, Z. Q. Chen, T. J. Prior, S. J. Archibald, G. C. Yin and T. J. Hubin, *Dalton Trans.*, 2015, **44**(27), 12210–12224.
- C. J. Anderson, T. J. Wadas, E. H. Wong and G. R. Weisman, *Q. J. Nucl. Med. Mol. Imaging*, 2008, **52**, 185–192.
- C. A. Boswell, X. Sun, W. Niu, G. R. Weisman, E. H. Wong, A. L. Rheingold and C. J. Anderson, *J. Med. Chem.*, 2004, **47**, 1465.
- C. J. Anderson and R. Ferdani, *Cancer Biother. Radiopharm.*, 2009, **24**, 379–393.
- R. Ferdani, D. J. Stigers, A. L. Fiamengo, L. Wei, B. T. Y. Li, J. A. Golen, A. L. Rheingold, G. R. Weisman, E. H. Wong and C. J. Anderson, *Dalton Trans.*, 2012, **41**, 1938–1950.
- K. J. Heroux, K. S. Woodin, D. J. Tranchemontagne, P. C. B. Widger, E. Southwick, E. H. Wong, G. R. Weisman, S. A. Tomellini, T. J. Wadas, C. J. Anderson, S. Kassel, J. A. Golen and A. L. Rheingold, *Dalton Trans.*, 2007, 2150–2162.
- A. Y. Odendaal, A. L. Fiamengo, R. Ferdani, T. J. Wadas, D. C. Hill, Y. Peng, K. J. Heroux, J. A. Golen, A. L. Rheingold, C. J. Anderson, G. R. Weisman and E. H. Wong, *Inorg. Chem.*, 2011, **50**, 3078–3086.
- J. E. Sprague, Y. Peng, A. L. Fiamengo, K. S. Woodin, E. A. Southwick, G. R. Weisman, E. H. Wong, J. A. Golen, A. L. Rheingold and C. J. Anderson, *J. Med. Chem.*, 2007, 2527–2535.
- X. Sun, M. Wuest, G. R. Weisman, E. H. Wong, D. P. Reed, C. A. Boswell, R. Motekaitis, A. E. Martell, M. J. Welch and C. J. Anderson, *J. Med. Chem.*, 2002, **45**, 469–477.
- B. P. Burke, C. S. Miranda, R. E. Lee, I. Renard, S. Nigam, G. S. Clemente, T. D'Huys, T. Ruest, J. Domarkas, J. A. Thompson, T. J. Hubin, D. Schols, C. J. Cawthorne and S. J. Archibald, *J. Nucl. Med.*, 2020, **61**(1), 123–128.
- G. C. Valks, G. McRobbie, E. A. Lewis, T. J. Hubin, T. M. Hunter, P. J. Sadler, C. Pannecouque, E. De Clercq and S. J. Archibald, *J. Med. Chem.*, 2006, **49**(21), 6162–6165.
- A. Khan, G. Nicholson, J. Greenman, L. Madden, G. McRobbie, C. Pannecouque, E. De Clercq, J. D. Silversides, R. Ullom, D. L. Maples, R. D. Maples, T. J. Hubin and S. J. Archibald, *J. Am. Chem. Soc.*, 2009, **131**, 3416–3417.
- R. Smith, D. Huskens, D. Daelemans, R. E. Mewis, C. D. Garcia, A. N. Cain, T. N. C. Freeman, C. Pannecouque, E. De Clercq, D. Schols, T. J. Hubin and S. J. Archibald, *Dalton Trans.*, 2012, **41**(37), 11369–11377.
- R. D. Maples, A. N. Cain, B. P. Burke, J. D. Silversides, R. Mewis, T. D'Huys, D. Schols, D. P. Linder, S. J. Archibald and T. J. Hubin, *Chem. – Eur. J.*, 2016, **22**, 12916–12930.
- A. N. Cain, C. F. T. N., K. D. Roewe, D. L. Cockriel, T. R. Hasley, R. D. Maples, E. M. A. Allbritton, T. D'Huys, T. van Loy, B. P. Burke, T. J. Prior, D. Schols, S. J. Archibald and T. J. Hubin, *Dalton Trans.*, 2019, **48**, 2785–2801.
- V. L. Goedken and D. H. Busch, *J. Am. Chem. Soc.*, 1972, **94**(21), 7355–7363.
- H. S. Winchell, J. Y. Klein, E. D. Simhon, R. L. Cyjon, O. Klein and H. Zaklad, *US pat.*, 5874573, 1999.
- H. S. Winchell, J. Y. Klein, E. D. Simhon, R. L. Cyjon, O. Klein and H. Zaklad, *US Pat.*, 6264966 B1, 2001.
- R. A. Wallace, T. J. Dunn and D. A. Moore, WO9519185A1, 1995.
- H. S. Winchell, J. Y. Klein, E. D. Simhon, R. L. Cyjon, O. Klein and H. Zaklad, WO9701360A2, 1997.
- H. S. Winchell, WO2003105827A1, 2003.
- H. S. Winchell, US20050112066A1, 2005.
- G. R. Weisman, E. H. Wong, D. C. Hill, M. E. Rogers, D. P. Reed and J. C. Calabrese, *Chem. Commun.*, 1996, 947–948.
- Z. Kovacs, E. A. Archer, M. K. Russell and A. D. Sherry, *Synth. Commun.*, 1999, **29**, 2817–2822.
- A. W. Addison, T. N. Rao, J. Reedijk, J. van Rijn and G. C. Verschoor, *J. Chem. Soc., Dalton Trans.*, 1984, 1349–1356.
- L. Hertli and T. A. Kaden, *Helv. Chim. Acta*, 1974, **57**, 1328–1333.